Table 1 Baseline MTM recommendations by medication category† and recommendation type among all INCREASE trial participants (N = 90)
Recommendations | MTM recommendations (total: N = 602) | ||
|---|---|---|---|
N | % | ||
Medication category† | Cardiometabolic | 138 | 22.9% |
Gastrointestinal | 102 | 16.9% | |
Pain management | 87 | 14.5% | |
Anticholinergics | 77 | 12.8% | |
Vitamins and supplements | 76 | 12.6% | |
Neuropsychiatric | 67 | 11.1% | |
Other | 55 | 9.1% | |
Recommendation type | Dose adjustment | 170 | 28.2% |
Switch to preferred agent | 166 | 27.6% | |
Drug and disease monitoring | 101 | 16.8% | |
Non-pharmacologic therapy | 77 | 12.8% | |
Discontinuation | 45 | 7.5% | |
Initiation of new medication | 43 | 7.1% | |